Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Mylan (NASDAQ: MYL ) has reported improved numbers in its fiscal Q4 and 2012 results, and it also shared news of an acquisition. For the quarter, the generic-drug company's revenue was $1.7 billion, against $1.5 billion in the same period the previous year. Net profit came in at $267 million ($0.65 per diluted share), which trumped Q4 2011's figure of $227 million ($0.53).
For the full year, the top line totaled $6.8 billion and the company netted $1.09 billion ($2.59 diluted EPS), against 2011's sales of $6.1 billion and $893 million ($2.04) net profit.
Mylan also proffered guidance for its fiscal 2013. It believes it will take in $7.0 billion-$7.4 billion in revenue and post a net profit of $1.06 billion-$1.18 billion ($2.75-$2.95 diluted EPS) for the year.
Separately, the company said it is to acquire Agila, a supplier of injectable products, from India-based Strides Arcolab. The price is $1.6 billion in cash, and the transaction is expected to be completed in Q4 2013, assuming regulatory approvals and "certain closing conditions," according to Mylan.